Gastroesophageal Reflux disease - Pipeline Insight, 2021
![](/report_cover/8047/gastroesophageal-reflux-disease-gerd-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Gastroesophageal Reflux disease - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gastroesophageal Reflux disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gastroesophageal Reflux disease: Overview
Gastro-oesophageal reflux disease (GORD) is a common condition, where acid from the stomach leaks up into the oesophagus (gullet). It usually occurs as a result of the ring of muscle at the bottom of the oesophagus becoming weakened. Read more about the causes of GORD. GORD causes symptoms such as heartburn and an unpleasant taste in the back of the mouth. It may just be an occasional nuisance for some people, but for others it can be a severe, lifelong problem. GORD can often be controlled with self-help measures and medication. Occasionally, surgery to correct the problem may be needed.
'Gastroesophageal Reflux disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroesophageal Reflux disease pipeline landscape is provided which includes the disease overview and Gastroesophageal Reflux disease treatment guidelines. The assessment part of the report embraces, in depth Gastroesophageal Reflux disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gastroesophageal Reflux disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastroesophageal Reflux disease Emerging Drugs
Further product details are provided in the report……..
Gastroesophageal Reflux disease: Therapeutic Assessment
This segment of the report provides insights about the different Gastroesophageal Reflux disease drugs segregated based on following parameters that define the scope of the report, such as:
Gastroesophageal Reflux disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroesophageal Reflux disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroesophageal Reflux disease drugs.
Gastroesophageal Reflux disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gastroesophageal Reflux disease - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gastroesophageal Reflux disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastroesophageal Reflux disease: Overview
Gastro-oesophageal reflux disease (GORD) is a common condition, where acid from the stomach leaks up into the oesophagus (gullet). It usually occurs as a result of the ring of muscle at the bottom of the oesophagus becoming weakened. Read more about the causes of GORD. GORD causes symptoms such as heartburn and an unpleasant taste in the back of the mouth. It may just be an occasional nuisance for some people, but for others it can be a severe, lifelong problem. GORD can often be controlled with self-help measures and medication. Occasionally, surgery to correct the problem may be needed.
'Gastroesophageal Reflux disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroesophageal Reflux disease pipeline landscape is provided which includes the disease overview and Gastroesophageal Reflux disease treatment guidelines. The assessment part of the report embraces, in depth Gastroesophageal Reflux disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastroesophageal Reflux disease R&D. The therapies under development are focused on novel approaches to treat/improve Gastroesophageal Reflux disease.
This segment of the Gastroesophageal Reflux disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastroesophageal Reflux disease Emerging Drugs
- Fexuprazan: Daewoong Pharmaceutical
- JP 1366: Jeil Pharmaceutical
Further product details are provided in the report……..
Gastroesophageal Reflux disease: Therapeutic Assessment
This segment of the report provides insights about the different Gastroesophageal Reflux disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastroesophageal Reflux disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Gastroesophageal Reflux disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroesophageal Reflux disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroesophageal Reflux disease drugs.
Gastroesophageal Reflux disease Report Insights
- Gastroesophageal Reflux disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastroesophageal Reflux disease drugs?
- How many Gastroesophageal Reflux disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroesophageal Reflux disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroesophageal Reflux disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastroesophageal Reflux disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daewoong Pharmaceutical
- Jeil Pharmaceutical
- Effexus Pharmaceutical
- Addpharma
- Fexuprazan
- JP 1366
- Lansoprazole/omeprazole
- AD 214
Introduction
Executive Summary
Gastroesophageal Reflux disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gastroesophageal Reflux disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gastroesophageal Reflux disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gastroesophageal Reflux disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fexuprazan : Daewoong Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
JP 1366: Jeil Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AD 214: Addpharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gastroesophageal Reflux disease Key Companies
Gastroesophageal Reflux disease Key Products
Gastroesophageal Reflux disease- Unmet Needs
Gastroesophageal Reflux disease- Market Drivers and Barriers
Gastroesophageal Reflux disease- Future Perspectives and Conclusion
Gastroesophageal Reflux disease Analyst Views
Gastroesophageal Reflux disease Key Companies
Appendix
Executive Summary
Gastroesophageal Reflux disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gastroesophageal Reflux disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Gastroesophageal Reflux disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gastroesophageal Reflux disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fexuprazan : Daewoong Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
JP 1366: Jeil Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AD 214: Addpharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Gastroesophageal Reflux disease Key Companies
Gastroesophageal Reflux disease Key Products
Gastroesophageal Reflux disease- Unmet Needs
Gastroesophageal Reflux disease- Market Drivers and Barriers
Gastroesophageal Reflux disease- Future Perspectives and Conclusion
Gastroesophageal Reflux disease Analyst Views
Gastroesophageal Reflux disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gastroesophageal Reflux disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gastroesophageal Reflux disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gastroesophageal Reflux disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gastroesophageal Reflux disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products